There are currently 46 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: Medvin Clinical Research - Metyas ( Site 0128), Covina, California +123 locations
Conditions: Systemic Lupus Erythematosus
Study of Systemic Lupus Erythematosus
Recruiting
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE. Patients 3 years of age and older with known or suspected SLE and their relatives may be eligible for this study. Patients will be evaluated with a medical history and physical examination, blood and urine tests. Other procedures may include: 1. Electrocardio... Read More
Gender:
ALL
Ages:
Between 3 years and 120 years
Trial Updated:
05/23/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Lupus Erythematosus
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Recruiting
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: GSK Investigational Site, Anniston, Alabama +90 locations
Conditions: Systemic Lupus Erythematosus
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
05/22/2025
Locations: AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona +338 locations
Conditions: Systemic Lupus Erythematosus
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/16/2025
Locations: UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California +198 locations
Conditions: Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/15/2025
Locations: Sl0044 50058, Avondale, Arizona +131 locations
Conditions: Systemic Lupus Erythematosus
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Recruiting
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/14/2025
Locations: Local Institution - 0100, Birmingham, Alabama +173 locations
Conditions: Systemic Lupus Erythematosus
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Recruiting
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Objective: To test whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with SLE. Eligibility: People aged 18 to 80 years with SLE. Design: Participants will undergo screening. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies.
Recruiting
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM. Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2025
Locations: Research Site, Anniston, Alabama +28 locations
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
05/12/2025
Locations: Pinnacle Research Group LLC, Anniston, Alabama +104 locations
Conditions: Systemic Lupus Erythematosus
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Recruiting
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/12/2025
Locations: Research Site, Las Vegas, Nevada
Conditions: Systemic Lupus Erythematosus